<DOC>
	<DOCNO>NCT00675285</DOCNO>
	<brief_summary>Leukotriene receptor antagonist ( LTRAs ) reduce fractional exhale nitric oxide ( FENO ) concentration child asthma , effect LTRA withdrawal FENO lung function unknown . We aim study effect treatment withdrawal montelukast , LTRA , airway inflammation reflect FENO lung function child asthma . A double-blind , randomize , placebo control , parallel group study undertaken 18 atopic child mild persistent asthma treat oral montelukast ( 5 mg/day 4 week ) 18 atopic child mild persistent asthma receive match placebo . A follow-up visit perform 2 week montelukast placebo withdrawal .</brief_summary>
	<brief_title>Effects Montelukast Children With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Children 6 14 yr old , step 1 step 2 GINA ( Global INitiative Asthma ) guideline exhale nitric oxide ( NO ) &gt; 20 PPB visit 2 symptom often twice day , FEV1 equal high 80 % predict value reversibility equal high 12 % salbutamol , positive provocation test methacholine , exercise regular medication , inhale shortacting beta2 agonist symptom relief Patient hospitalize Patient FEV1 &lt; 80 % predict visit 1 Patient 2 nighttime awakening asthma per week pef variability 30 % upper respiratory infection previous 3 week treatment glucocorticoid LTRAs previous 4 week treatment inhale glucocorticoid 4 week previous year</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>airway inflammation</keyword>
	<keyword>childhood asthma</keyword>
	<keyword>fractional exhale nitric oxide</keyword>
	<keyword>leukotriene receptor antagonist</keyword>
	<keyword>lung function</keyword>
</DOC>